Scholarlink

Background <p>The use of thermal ablation of liver tumors is rapidly increasing. This is despite a lack of high-level evidence of the oncologic efficacy of ablation. Ablation is most often used in cases where resection is not possible, but as the technique has improved it is increasingly used as a substitute for resection.</p> Patients and Methods <p>New Comet is an international multicenter randomized controlled double-blinded, non-inferiority trial comparing thermal ablation to resection of colorectal liver metastases. It will include 230 patients with colorectal liver metastases (up to 5 lesions, tumor size up to 3 cm) where thermal ablation and resection both are considered suitable treatment options for all lesions. The patients are randomized to either resection or ablation, and all lesions in each patient are treated with the same modality. Complete ablation will be verified with intraoperative computed tomography and ablation confirmation software.</p> Conclusions <p>The primary endpoint is local tumor recurrence at 12 months. Secondary endpoints include overall survival, disease-free survival, time to surgical failure, health-related quality of life, complications, and cost-effectiveness (trial registration no.: NCT05129787).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Randomized Controlled Trial of Resection Versus Thermal Ablation of Colorectal Cancer Liver Metastases (New Comet): Study Protocol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月26日

查看全文
  • Ingrid Schrøder Hansen,
  • Karina Roheim Lappen,
  • Kristoffer Watten Brudvik,
  • Bård Ingvald Røsok,
  • Ida Björk,
  • Daniel Østergaard,
  • Marit Helen Andersen,
  • Egidijus Pelanis,
  • Andreas Westenvik Espinoza,
  • Per Steinar Halvorsen,
  • Sheraz Yaqub,
  • Kristoffer Lassen,
  • Bjørn von Gohren Edwin,
  • Trygve Syversveen,
  • Åsmund Avdem Fretland

摘要

Background

The use of thermal ablation of liver tumors is rapidly increasing. This is despite a lack of high-level evidence of the oncologic efficacy of ablation. Ablation is most often used in cases where resection is not possible, but as the technique has improved it is increasingly used as a substitute for resection.

Patients and Methods

New Comet is an international multicenter randomized controlled double-blinded, non-inferiority trial comparing thermal ablation to resection of colorectal liver metastases. It will include 230 patients with colorectal liver metastases (up to 5 lesions, tumor size up to 3 cm) where thermal ablation and resection both are considered suitable treatment options for all lesions. The patients are randomized to either resection or ablation, and all lesions in each patient are treated with the same modality. Complete ablation will be verified with intraoperative computed tomography and ablation confirmation software.

Conclusions

The primary endpoint is local tumor recurrence at 12 months. Secondary endpoints include overall survival, disease-free survival, time to surgical failure, health-related quality of life, complications, and cost-effectiveness (trial registration no.: NCT05129787).